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Severe malaria is most commonly associated with Plasmodium falciparum. Plasmodium vivax is increasingly
recognized as being capable of causing severe disease. In contrast, Plasmodium ovale is considered as a cause of
benign disease and evidence supporting the occurrence of severe or complicated ovale infection is rare. This report
describes a case of severe P. ovale infection in a patient presenting with jaundice, respiratory distress, severe
thrombocytopenia, petechiae, and hypotension. He had no apparent underlying risk factors for severe disease.
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Malaria is the most important parasitic disease of man [1].
According to the World Health Organization (WHO) an
estimated 3.3 billion people are at risk of malaria [2]. An-
nually there are over 200 hundred million clinical cases of
malaria with an estimated 660,000 deaths, 90% of which
occur in sub-Saharan Africa, where children under five
years are most severely affected [2].
Disease in humans is caused by five species of apicom-
plexan parasites belonging to the genus Plasmodium [1].
Plasmodium falciparum is most commonly associated
with severe disease [1-3]. Severe malaria is also known to
occur with Plasmodium vivax and Plasmodium knowlesi
[1,4,5]. Infection with Plasmodium malariae is generally
benign, but has been associated with nephrotic syndrome
and severe anaemia [3,6-8].
Although the clinical presentations of Plasmodium
ovale and P. vivax infections largely overlap, severe dis-
ease due to P. ovale is extremely rare [1,3,9]. This case
report describes an uncommonly severe case of ovale
malaria in a patient with no apparent underlying risk
factors for severe disease. The existing literature docu-
menting severe or complicated presentations of P. ovale
infection is reviewed.* Correspondence: strydom.kathy@gmail.com
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A 42-year-old male, with no significant previous medical
history, was referred by a general practitioner to the
Steve Biko Academic Hospital, Pretoria, South Africa.
The patient presented with fever, nausea and vomiting,
general body pains and shortness of breath. He com-
plained of feeling weak and tired for the last three weeks.
In the preceding six months he had worked in two
malaria-endemic regions: Kalia in the north-west region
of Guinea, and most recently Mozambique, from where
he had returned a month previously. He had not taken
malaria chemoprophylaxis during his stay in these areas.
Upon physical examination the patient was awake and
alert, with no signs of meningism. He was visibly jaun-
diced. Abdominal examination revealed a tender right
upper quadrant, there were bilateral fine crepitations on
auscultation of the lungs, and petechiae were visible on
his upper and lower limbs. The patient was hypotensive
(blood pressure 78/58 mmHg), tachycardic (pulse rate
110 per minute) and tachypnoeic (respiratory rate 28 per
minute). The temperature was 39.5°C. The chest x-ray
was unremarkable.
Laboratory evaluation showed a marked thrombocytopenia
(platelets 23 × 109/l), mildly deranged renal function (urea
13.2 mmol/l, creatinine 157 μmol/l) and liver function tests
(total bilirubin 96 μmol/l, alanine transaminase 43 U/l, as-
partate transaminase 74 U/l, γ-glutamyltransferase 66 U/l).
The patient had markedly elevated inflammatory markers
(C-reactive protein 121.7 mg/l and procalcitonin 105.6 μg/l).l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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examination of Giemsa-stained blood smears, showing
characteristic P. ovale parasites (Figure 1). The parasit-
aemia was 1.4%. Rapid diagnostic tests for P. falciparum
antigen (histidine-rich protein 2) were repeatedly nega-
tive. Mixed Plasmodium species infection was excluded
and the diagnosis of P. ovale malaria was confirmed by
multiplex PCR [10,11].
The patient was admitted to high care and treated
with a course of intravenous quinine (600 mg eight
hourly) and doxycycline (100 mg twelve hourly). Ceftri-
axone was added to cover for possible bacterial sepsis.
The septic screen investigations, which comprised two
sets of blood cultures and a urine culture, were negative.
The timing of the blood cultures in relation to antibiotic
administration is unclear.
The patient demonstrated a good clinical response to
treatment, and he was stepped down to a general ward.
Subsequent laboratory evaluations showed an improve-
ment in full blood count, renal and liver functions as
well as inflammatory markers, which returned to normal
before discharge. Primaquine, 30 mg orally for 14 days
was administered to eradicate hypnozoites and prevent
possible relapses.Figure 1 Giemsa-stained thick and thin smears. A. Trophozoites of P. ova
and immature schizonts of P. ovale in a Giemsa-stained thin film. Note slightly
James’ dots.Discussion
Endemic transmission of P. ovale is traditionally de-
scribed as limited to sub-Saharan Africa and the islands
of the western Pacific [9]. Infections with P. ovale have
also been documented from India, the Middle East and
parts of Southeast Asia [6,9]. Two non-recombining
sympatric forms of P. ovale occur globally [12]. Plasmo-
dium ovale curtisi (classic type) and Plasmodium ovale
wallikeri (variant type) have been proposed as two dis-
tinct species [12,13].
Much of what is currently known regarding the epi-
demiology of P. ovale is based upon surveys utilising
light microscopy as diagnostic tool [6]. From these sur-
veys, the prevalence of P. ovale is generally considered
to be low and ranges between 3-5% and greater than
10% in areas of West and Central Africa [6]. The utility
of light microscopy is limited by difficulties in distin-
guishing between P. ovale and P. vivax in smears, as
well as the low parasitaemias characteristic of P. ovale
infection. In addition, immunochromatography-based
rapid diagnostic tests display poor sensitivity for the
detection of P. ovale infection [14,15]. This may lead to
underestimating the true burden of disease as is evident
when more sensitive diagnostic modalities, such asle in a Giemsa-stained thick smear. B. Trophozoites and C, D. Trophozoites
enlarged, fimbriated and oval-shaped infected red blood cells, with
Table 1 Summary of published cases of severe and complicated P. ovale infection
Reference Patient
age
Gender Medical history Travel history Prophylaxis Time to
presentation
Parasitaemia WHO or other
severity criteria
Treatment Outcome








IV quinine, 14 days
primaquine
Recovered
Lee et al. [16] 31 yr Female None Ghana Mefloquine 10 months 0.1% ARDS Chloroquine, 14 days
primaquine
Recovered
Rojo Marcos et al. [17] 43 yr Male Hypertensive, diabetic Nigeria None N/S 6,000/μL ARDS Chloroquine, 14 days
primaquine
Recovered













Roze et al. [19] 24 yr Male Tuberous sclerosis Chad, Ivory Coast Doxycycline 1 year 0.1% ARDS Chloroquine then
changed to quinine
Recovered
Lau et al. [20] 59 yr Male None Victoria Island,
Nigeria








Hashimi et al. [21] 31 yr Male Previous pulmonary




N/S 7 months 0.2% ARDS IV quinine Demised
Facer et al. [23] 51 yr Female N/S Ghana None 12 days 1.8% Splenic rupture None Demised





18 months N/S Splenic rupture Chloroquine and
primaquine
Recovered
Cinquetti et al. [25] 34 yr Male None Senegal 2002,
Ivory Coast 2004
Doxycycline 2-4 years 0.001% Splenic infarction IV quinine Recovered
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employed [6].
Plasmodium ovale is known to cause mild disease with
a low parasitaemia [6,9]. Literature describing severe or
complicated cases of P. ovale infection is limited. These
rare reports include six cases complicated by acute re-
spiratory distress syndrome (ARDS)(one of which further
complicated by renal failure and metabolic acidosis), two
cases of splenic rupture, and a single case of splenic in-
farction [16-25]. Clinical and therapeutic data for these
cases are shown in Table 1.
The current WHO treatment guidelines for severe
malaria recommend intravenous (IV) artesunate for the
treatment of severe malaria due to all Plasmodium spe-
cies [26]. Intravenous artesunate is currently not regis-
tered in South Africa for clinical use and is only available
for named patients on application under Section 21 of the
Medicines and Related Substances Act, usually at selected
sentinel hospitals through the current artesunate access
programme. The patient discussed in this case report was
treated with IV quinine, which according to the current
South African treatment guidelines, is still the treatment
of choice for severe malaria in adult patients if IV artesu-
nate is not readily available [27].
The pathophysiology of P. falciparum as the leading
cause of severe malaria has been examined extensively.
Various parasite, host, geographic and social factors
contribute to severe disease manifestations; however,
sequestration of mature parasitized red blood cells is
considered to be the key pathogenic event [28,29].
Plasmodium vivax, long considered to cause benign in-
fection, is increasingly recognised as a cause of severe mal-
aria [30,31]. Similar to P. falciparum infection, multiple
factors contribute to severe disease [30]. Evidence is emer-
ging that P. vivax infected red blood cells can also cytoad-
here and sequestrate in the microvasculature, but to a
lesser extent than P. falciparum [32]. It remains to be elu-
cidated to what degree sequestration contributes to severe
disease manifestations in vivax infections [30,32].
The pathophysiological correlates and risk factors for
severe P. ovale infection are not yet fully established.
Reports of severe ovale infection remain rare; however,
when the diagnostic difficulties both in the detection of
a low parasitaemia and distinguishing P. ovale from P.
vivax, based on traditional light microscopy is taken into
account, severe cases of ovale malaria may actually be
underreported.
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